Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY<sup>®</sup> study.

导出 OA

翻译打印收藏纠错

作者： Martin,Prázný ^[1] ; Lyudmila,Suplotova ^[2] ; Janusz,Gumprecht ^[3] ; Zdravko,Kamenov ^[4] ; Tibor,Fülöp ^[5] ; Alexey,Medvedchikov ^[6] ; Doron,Rosenzweig ^[7] ; Milos,Aleksandric ^[7]

作者单位： 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. martin.prazny@outlook.com. ^[1] Tyumen State Medical University, Tyumen, Russian Federation. ^[2] Department of Internal Medicine, Diabetology and Nephrology in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. ^[3] Department of Internal Medicine, Medical University Sofia, Sofia, Bulgaria. ^[4] Clinic of Endocrinology, University Hospital Alexandrovska, Sofia, Bulgaria. ^[5] Department of Cardiology and Heart Surgery, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary. ^[6] Boehringer Ingelheim RCV GmbH and Co. KG, Vienna, Austria. ^[7]

关键词 Cardiovascular disease (CVD)Cardiovascular outcomes trials (CVOTs)Cardiovascular safety Chronic kidney disease (CKD)Dipeptidyl peptidase-4 inhibitors (DPP4i)Glucagon-like peptide-1 receptor agonists (GLP-1 RA)Glucose-lowering drug Sodium-glucose cotransporter-2 inhibitors (SGLT2i)Type 2 diabetes